Rosuvapac

Rosuvapac

rosuvastatin

Manufacturer:

Pacific Pharma (Korea)

Distributor:

AA Medical
Concise Prescribing Info
Contents
Rosuvastatin Ca
Indications/Uses
Primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet & other non-pharmacological treatments (eg, exercise, wt reduction) is inadequate. Homozygous familial hypercholesterolaemia as an adjunct to diet & other lipid lowering treatments (eg, LDL apheresis) or if such treatments are not appropriate.
Dosage/Direction for Use
Initially 5 or 10 mg once daily in both statin-naive or patients switched from another HMG-CoA reductase inhibitor, may be adjusted to the next dose level after 4 wk, if necessary. Patient w/ severe hypercholesterolaemia at high CV risk (w/ familial hypercholesterolaemia) Max: 40 mg.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Active liver disease (including unexplained, persistent elevations of serum transaminases & elevation >3x the ULN). Severe renal impairment (CrCl <30 mL/min). Myopathy. Patients receiving concomitant ciclosporin.
Special Precautions
Proteinuria. Myalgia, myopathy & rhabdomyolysis. Consider assessment of renal function during routine follow-up of patients treated w/ 40 mg. In combination w/ ezetimibe.
Adverse Reactions
Headache, dizziness; constipation, nausea, abdominal pain; myalgia; asthenia.
MIMS Class
Dyslipidaemic Agents
ATC Classification
C10AA07 - rosuvastatin ; Belongs to the class of HMG CoA reductase inhibitors. Used in the treatment of hyperlipidemia.
Presentation/Packing
Form
Rosuvapac FC tab 10 mg
Packing/Price
3 × 10's
Form
Rosuvapac FC tab 20 mg
Packing/Price
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in